Skip to main content

Table 1 Demographics and baseline characteristics of study participants

From: Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study

  Total (n= 30) Intravitreal (n = 15) Subconjunctival (n = 15)
Gender (% (n))    
 Male 50 (15) 60 (9) 40 (6)
 Female 50 (15) 40 (6) 60 (9)
Age (year (± SD)) 47 (±18.8) 45 (±19.8) 48 (±18.2)
Race (% (n))    
 Caucasian 77 (23) 73 (11) 80 (12)
 African/American 20 (6) 20 (3) 20 (3)
 Others 3 (1) 7 (1) -
Disease category (% (n))    
 Category 1: active without treatment 23 (7) 20 (3) 27 (4)
 Category 2: active with treatment 50 (15) 60 (9) 40 (6)
 Category 3: inactive with treatment 27 (8) 20 (3) 33 (5)
Anatomical location (% (n))    
 Intermediate 30 (9) 33 (5) 27 (4)
 Posterior 60 (18) 60 (9) 60 (9)
 Panuveitis 10 (3) 7 (1) 13 (2)
Underlying disease (% (n))    
 Birdshot choroidopathy 13 (4) 7 (1) 20 (3)
 Sarcoidosis 13 (4) - 27 (4)
 Punctate inner choroidopathy 7 (2) 7 (1) 7 (1)
 Multifocal choroiditis 7 (2) 13 (2) -
 Vogt-Koyanagi-Harada 3 (1) 7 (1) -
 Idiopathic 57 (17) 67 (10) 47 (7)
Macular thickness (CMT)    
 Macular edema (% (n)) 37 (11) 47 (7) 27 (4)
 Central macular thickness (mean ± SD) 356 ± 149 377 ± 178 334 ± 116
 CMT in patients without ME (mean ± SD) 269 ± 28 257 ± 31.6 278 ± 22.5
 CMT in patients with ME (mean ± SD) 505 ± 156 515 ± 176 488 ± 134
Corticosteroid use (% (n)) 67 (22) 80 (12) 67 (10)
Corticosteroid dose (mg/day)    
 Category 1 (mean ± SD) NA NA NA
 Category 2 (mean ± SD) 28.2 ± 16.2 28.3 ± 18 27.9 ± 14.9
 Category 3 (mean ± SD) 7.1 ± 3.0 7.3 ± 2.1 7.0 ± 4.0
Prior IMT use (% (n)) 25 (7) 20 (3) 27 (4)
VA in ETDRS score (Snellen equivalent)    
 Category 1 (mean ± SD) 62 ± 13 (20/63) 55 ± 6.2 (20/80) 68 ± 15.4 (20/40)
 Category 2 (mean ± SD) 70 ± 17 (20/40) 66 ± 16.8 (20/50) 75 ± 18.9 (20/32)
 Category 3 (mean ± SD) 72 ± 23 (20/40) 66 ± 23.1 (20/50) 75 ± 24.2 (20/32)
  1. n, number; SD, standard deviation; CMT, central macular thickness; NA, not applicable; VA, visual acuity; ME, macular edema.